-
Product Insights
Dedifferentiated Liposarcoma - Drugs In Development, 2024
Empower your strategies with our Dedifferentiated Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Dedifferentiated liposarcoma (DDLPS) is a rare and aggressive type of cancer that arises from fat cells. It usually occurs in the limbs or the abdomen, and can cause pain, swelling, or a lump under the skin. DDLPS is a subtype of liposarcoma that develops from a low-grade tumor called well-differentiated liposarcoma (WDLS). The tumor undergoes a transformation to a high-grade sarcoma that...
-
Product Insights
Lymphoblastic Lymphoma - Drugs In Development, 2024
Empower your strategies with our Lymphoblastic Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Lymphoblastic lymphoma (LL) is a rare and aggressive type of non-Hodgkin lymphoma (NHL) that affects immature lymphocytes called lymphoblasts. It can originate from either B-cell or T-cell lymphoblasts, but it is more common in T cells. LL usually involves the lymph nodes in the chest, but it can also affect the bone marrow, the brain and spinal cord, and other organs. LL...
-
Product Insights
Papillary Thyroid Cancer - Drugs In Development, 2024
Empower your strategies with our Papillary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 75% to 85% of all cases. It affects more women than men and can occur at any age, but especially between 30 and 50 years old. PTC is usually slow-growing and well-differentiated, meaning it resembles normal thyroid cells. However, it can also spread to the lymph nodes...
-
Product Insights
Nodal Marginal Zone B-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Nodal marginal zone B-cell lymphoma (NMZL) is a rare type of non-Hodgkin lymphoma that affects the lymph nodes. It is a slow-growing cancer that can sometimes become aggressive. NMZL is more common in older adults, but it can occur in younger people as well. The exact cause of NMZL is unknown, but some genetic factors may be involved. NMZL...
-
Product Insights
Neuroendocrine Carcinoma - Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine carcinoma (NEC) is a rare type of cancer that arises from neuroendocrine cells, which are cells that have both nerve and hormone functions. NEC can occur in various organs, such as the lungs, pancreas, stomach, intestines, appendix, rectum, breast, kidney, ovaries, or testicles. NEC can be classified into well-differentiated or poorly differentiated tumors, depending on how they look under the microscope...
-
Product Insights
Splenic Marginal Zone B-Cell Lymphoma - Drugs In Development, 2024
Empower your strategies with our Splenic Marginal Zone B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Splenic marginal zone lymphoma (SMZL) is a rare type of B-cell lymphoma that affects the spleen, bone marrow, and sometimes the blood. It is a low-grade neoplasm that originates from the germinal centers of the splenic white pulp. The neoplastic cells are small lymphocytes and larger transformed lymphoblasts that invade the mantle and marginal zones of the spleen and...
-
Product Insights
Chordoma - Drugs In Development, 2024
Empower your strategies with our Chordoma – Drugs In Development, 2024 report and make more profitable business decisions. Chordoma is a rare type of bone cancer that occurs in the bones of the spine or the base of the skull. It begins in cells that once made up structures in the developing embryo that then developed into the disks of the spine. Most of these cells are gone by the time of birth or soon after, but sometimes a few remain...
-
Product Insights
Meningioma - Drugs In Development, 2024
Empower your strategies with our Meningioma – Drugs In Development, 2024 report and make more profitable business decisions. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid, and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of...
-
Product Insights
Primary CNS Lymphoma - Drugs In Development, 2024
Empower your strategies with our Primary CNS Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary CNS lymphoma (PCNSL) is a rare extranodal lymphoma that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. It is a subtype on, and one of the most aggressive forms of, diffuse large B-cell lymphoma. PCNSL is more common in immunosuppressed patients, such as those with HIV/AIDS or transplant recipients, and is often associated with...
-
Product Insights
Hormone-Sensitive Prostate Cancer - Drugs In Development, 2024
Empower your strategies with our Hormone-Sensitive Prostate Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that responds to hormone therapy, which aims to reduce or block the production or action of androgens such as testosterone. Androgens are male sex hormones that stimulate the growth of normal and cancerous prostate cells. Most prostate cancers are initially hormone-sensitive, but they may become castration-resistant over time, meaning that they...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.